Sanofi's CMO takes on chief digital officer role; Parexel nabs four high-profile FDA staffers; and Nimbus poaches Janssen's discovery head as CSO.
Glenmark is rolling all of the new molecular entities in its pipeline into a separate U.S. company in an effort to speed the programs to market.
90% of clinical trials will meet their enrollment goals if their original timelines are doubled. WCG breaks down the barriers to ramping up and meeting patient…
MUSC and Medtronic have signed on to a value-based healthcare collaboration, to reduce the cost of chronic conditions through standard care pathways.
Sight Diagnostics, maker of point-of-care blood diagnostic hardware, raised $27.8 million to continue its expansion and fund U.S. regulatory efforts.
Passage Bio reeled in $115.5 million, which will support the development of five programs aimed at treating rare monogenic central nervous system diseases.
Digital drug miner Nimbus Therapeutics has brought on Janssen’s global head of lead discovery, Peter Tummino, to serve as its CSO.
University of Geneva scientists showed how pancreatic cells that normally don't produce insulin can be converted to produce the hormone.
Axovant spun off its small molecule team into Arvelle Therapeutics, as it continues its march toward a sole focus on gene therapies.
The funding will advance Vor's lead asset, an engineered hematopoietic stem cell therapy for acute myeloid leukemia.
Motif Bio’s hope of adding to the antibiotic armamentarium for serious bacterial infections has just been dealt a blow by the FDA.